Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05013944 · ClinicalTrials.gov registry record
AnovaOS Network Powered Patient Registry
A clinical trial of Neoplasms and Infectious Disease, sponsored by Anova Enterprises.
- Recruiting
- Registry status
- 100,000
- Enrollment target
- 1
- Study location
NCT05013944: Recruiting study of Neoplasms and Infectious Disease, sponsored by Anova Enterprises.
NCT05013944 is a study of Neoplasms and Infectious Disease that is actively recruiting participants, run by Anova Enterprises. The registered enrollment target is 100,000 participants, above the 988-participant average among 158 other Neoplasms trials with a reported enrollment target (10021% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05013944, a study of Neoplasms and Infectious Disease, is actively recruiting participants, sponsored by Anova Enterprises.
- RECRUITING
- Registry status
- 100,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is the development, implementation and management of a registry of patient data that captures clinically meaningful, real-world, data on the diagnosis, nature, course of infection, treatment(s) and outcomes in patients with complex disease globally.
Conditions Studied
Study Locations (1)
Illinois
- Anova Enterprises, Inc. - Arlington Heights
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100,000 participants |
| Start Date | 2021-09-01 |
| Est. Completion | 2026-08-31 |
What NCT05013944 shows while recruiting
NCT05013944 is an observational study that tracks outcomes without assigning an intervention. Its 100,000 participants enrollment target places it among the larger protocols in the corpus, above the 988-participant average among 158 other Neoplasms trials with a reported enrollment target (10021% higher).
The record links to 10 conditions, with Neoplasms appearing as the primary indexed condition, and to 0 interventions.
NCT05013944 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05013944 about?
NCT05013944 is a clinical study titled "AnovaOS Network Powered Patient Registry". The objective of this study is the development, implementation and management of a registry of patient data that captures clinically meaningful, real-world, data on the diagnosis, nature, course of infection, treatment(s) and outcomes in patients with complex disease globally.
What is the current status of trial NCT05013944?
This trial is currently recruiting. The enrollment target is 100,000 participants. The study started on 2021-09-01. Estimated completion is 2026-08-31.
What conditions does trial NCT05013944 study?
This clinical trial studies the following conditions: Neoplasms, Infectious Disease, Diseases of the Blood and Blood-Forming Organs and Certain Disorders Involving the Immune Mechanism (D50-D89), Endocrine, Nutritional and Metabolic Diseases (E00-E89), Mental and Behavioural Disorders.
Who is sponsoring clinical trial NCT05013944?
This trial is sponsored by Anova Enterprises, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05013944 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05013944's enrollment target sits among peer trials
100,000 1st of 158 higher than 158 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
Real World Registry for Use of the Ion Endoluminal System
RECRUITING
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Endometrial Cell Collection With the PadKit
RECRUITING · NA
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Resilience in East Asian Immigrants for Advance Care Planning Discussions
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02620852 · 100,000 participants · NA
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
- NCT03277365 · 100,000 participants · NA
MyGeneRank: A Digital Platform for Next-Generation Genetic Studies
- NCT04281823 · 100,000 participants
DeBakey Cardiovascular Magnetic Resonance Study
- NCT04869111 · 100,000 participants · NA
The BrainHealth Project
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI